Delphinus Medical Technologies Raises $12 Million as Footprint Continues to Expand

Funds to Drive Continued Commercialization of SoftVue™ 3D Whole Breast Ultrasound Tomography System for Screening Women With Dense Breasts

Delphinus Medical Technologies, the pioneers of dense breast medical imaging, announced today that it raised $12 million in growth capital from Trinity Capital Inc. (NASDAQ: TRIN), a leading provider of diversified financial solutions to growth-stage companies.

Delphinus’ transformational SoftVue™ 3D Whole Breast Tomography System was approved by the U.S. Food & Drug Administration (FDA) in October 2021 as an adjunct to digital mammography in the screening of asymptomatic women with dense breast tissue. This disruptive technology not only redefines the standards for early breast cancer detection, but also enhances patient comfort, and reduces unnecessary callbacks.

Dense breast tissue is common, affecting 40 percent of women, and making them four to six times more likely to develop breast cancer. Compounding this increased risk, dense breast tissue appears white on mammograms, as do cancerous masses, causing clinicians to miss roughly half of new cancer cases in this population of women. When paired with screening mammography, SoftVue has been shown to identify up to 20 percent more cancers, while also reducing false positives and decreasing unnecessary call-backs and biopsies.

“Mammography alone is not enough to address the screening needs of dense breast patients,” said Mark J. Forchette, president and CEO of Delphinus Medical Technologies. “SoftVue provides a comprehensive solution that enables providers to transform their patients’ clinical experience. Our relationship with Trinity Capital helps us make impactful investments in execution, to help our clinical partners embrace this innovation, and serve the unmet needs of patients with dense breast tissue that SoftVue was designed to address.”

The Trinity funding enables the Delphinus team to continue to scale operations, broadening its impact on the global healthcare community. Delphinus continues to expand its commercial foundation, most recently adding Corewell Health to the roster of clinical sites that are building robust dense breast screening programs to benefit patients. Earlier this year, Delphinus announced the expansion of its list of commercial and research partners with a new installation at The University of Rochester Medical Center.

“We are excited to be a part of Delphinus’ journey as they innovate life-saving medical imaging technology,” said Lauren Cosentino, managing director, life sciences, at Trinity. “We believe in their team and are excited to help accelerate their growth trajectory.”

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy